News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Vijaya Natarajan

Articles by Vijaya Natarajan

13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

ByAmanda Reynolds,Jonathan Klein,Joshua Feinberg,Bayle Smith-Salzberg,Pasang Sherpa,Vijaya Natarajan,Fleure Gallant,Ashley Anderson,Mukuhi Ng’ang’a

July 4th 2025

58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients

ByJonathan Klein,Joshua Feinberg,Mukuhi Ng’ang’a,Ashley Anderson,Vijaya Natarajan,Pasang Sherpa,Fleure Gallant,David Berlach,Ezekiel Sanchez,Charusheela Andaz

May 12th 2024

51 The Race, Staging, and Clinical Correlations With Genetic Mutations Diagnosed in Breast Cancer Patients of Multiethnicity Background

ByNay Yee Wint Kyaw,Vijaya Natarajan,Theresa Durana,Yiqing Xu

April 26th 2023

29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients

ByVijayashree Murthy,Dana Borgen,Joshua Feinberg,Kristin E. Rojas,Vijaya Natarajan,Yocasta Mejia,Michael Silver,Charusheela Andaz,Donna-Marie Manasseh

May 6th 2022

Latest Updated Articles

Trending on CancerNetwork

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Combining a PCNA Inhibitor with KRAS-Targeting Agents in PDAC

Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial

Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?

Tovecimig/Paclitaxel Meets PFS, Misses OS End Points in 2L Biliary Tract Cancer